40 commercial payer policies list J3380. See each policy's status for the code and its official source. Listing a code is not a coverage decision: read each policy’s source for the requirements that apply.
Free account. Policy pages stay open to everyone.
40 policies from 22 payers
Summary of the payer’s published policy. Not a coverage determination — confirm with the payer before submitting.
Codes labeled “Inferred from policy title” are not listed in the policy document; Backwork attached them because the policy title names the drug.
| Policy | Effective | Status of J3380 |
|---|---|---|
| Entyvio Intravenous (vedolizumab) | Not recorded | Prior auth requiredInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Entyvio Intravenous (vedolizumab)Effective 06/01/2024 - 05/31/2025 | Jun 1, 2024 | Prior auth requiredInferred from policy title |
| Entyvio Intravenous (vedolizumab)Effective 06/01/2025 - 05/31/2026 | Jun 1, 2025 | Prior auth requiredInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
|---|
| Vedolizumab (Entyvio)Effective 07/01/2022 - 07/31/2023 | Jul 1, 2022 | Prior auth requiredInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
|---|
| Vedolizumab (Entyvio)Effective 08/01/2021 - 06/30/2022 | Aug 1, 2021 | Prior auth requiredInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
|---|
| Vedolizumab (Entyvio)Effective 08/01/2023 - 05/31/2024 | Aug 1, 2023 | Prior auth requiredInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
|---|
| Vedolizumab (Entyvio)Effective 10/01/2019 - 09/30/2020 | Oct 1, 2019 | Prior auth requiredInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
|---|
| Vedolizumab (Entyvio)Effective 10/01/2020 - 07/31/2021 | Oct 1, 2020 | Prior auth requiredInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
|---|
| Vedolizumab (Entyvio)Effective 11/02/2018 - 09/30/2019 | Nov 2, 2018 | Prior auth requiredInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
|---|
| Policy | Effective | Status of J3380 |
|---|---|---|
| Entyvio (Vedolizumab) | Aug 1, 2026 | Covered |
| Provider Administered Drugs – Site of Care | Oct 1, 2026 | Covered |
| Entyvio (Vedolizumab) – Commercial and Individual Exchange Medical Benefit Drug Policy | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Entyvio (Vedolizumab) – Community Plan Medical Benefit Drug Policy | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of J3380 |
|---|---|---|
| Vedolizumab (Entyvio) for Injection for Intravenous Use | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Vedolizumab (Entyvio) for Injection for Intravenous Use | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of J3380 |
|---|---|---|
| Specialty Medication Administration Site of Care | Jan 1, 2026 | Covered |
| Vedolizumab | Apr 1, 2026 | Covered |
| Policy | Effective | Status of J3380 |
|---|---|---|
| Specialty Medication Administration Site of Care | Jan 1, 2026 | Covered |
| Vedolizumab | Apr 1, 2026 | Covered |
| Policy | Effective | Status of J3380 |
|---|---|---|
| Specialty Medication Administration Site of Care | Jan 1, 2026 | Covered |
| Vedolizumab | Apr 1, 2026 | Covered |
| Policy | Effective | Status of J3380 |
|---|---|---|
| Specialty Medication Administration Site of Care | Jan 1, 2026 | Covered |
| Vedolizumab | Apr 1, 2026 | Covered |
| Policy | Effective | Status of J3380 |
|---|---|---|
| Vedolizumab (Entyvio) for Injection for Intravenous Use | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Vedolizumab (Entyvio) for Injection for Intravenous Use | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of J3380 |
|---|---|---|
| Entyvio (Vedolizumab) | Aug 1, 2026 | Covered |
| Provider Administered Drugs – Site of Care | Oct 1, 2026 | Covered |
| Policy | Effective | Status of J3380 |
|---|---|---|
| Guillain-Barre Syndrome Treatments | Sep 22, 2023 | Covered |
| Policy | Effective | Status of J3380 |
|---|---|---|
| Vedolizumab (e.g., Entyvio) for Inflammatory Bowel Disease | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of J3380 |
|---|---|---|
| Entyvio (Vedolizumab) Policy | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of J3380 |
|---|---|---|
| ENTYVIO (VEDOLIZUMAB) | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of J3380 |
|---|---|---|
| Vedolizumab Entyvio | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of J3380 |
|---|---|---|
| Entyvio (vedolizumab) for Inflammatory Bowel Disease. Medical Policy MP 5.01.662 Entyvio (vedolizumab) for Inflammatory Bowel Disease DISCLAIMER/INSTRUCTIONS FOR USE This medical policy | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of J3380 |
|---|---|---|
| Vedolizumab (Entyvio) | Jun 11, 2014 | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of J3380 |
|---|---|---|
| Vedolizumab (Entyvio) | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of J3380 |
|---|---|---|
| Vedolizumab (Entyvio) | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of J3380 |
|---|---|---|
| 00439 vedolizumab (Entyvio) | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of J3380 |
|---|---|---|
| Entyvio (vedolizumab) | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of J3380 |
|---|---|---|
| Entyvio Subcutaneous Products | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of J3380 |
|---|---|---|
| Entyvio (Vedolizumab) | Aug 1, 2026 | Covered |